Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Non-triple-negative Metastatic Breast Cancer
NCT01653561Phase 2Completed
- Sponsor
- Fudan University
- Start
- Nov 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in breast cancer, sponsored by Fudan University. Started Nov 2011; status: completed.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01653561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01653561.